| [1] |
de Almeida R,Nakamura CN,de Lima Fontes M,et al.Enhanced immunization techniques to obtain highly specific monoclonal antibodies[J].MAbs,2018,10(1):46-54.
|
| [2] |
Yu S,Li A,Liu Q,et al.Recent advances of bispecific antibodies in solid tumors[J].J Hematol Oncol,2017,10(1):155.
|
| [3] |
Sado Y,Inoue S,Tomono Y,et al.Monoclonal suncus antibodies:generation of fusion partners to produce suncus-suncus hybridomas[J].Acta Histochem Cytochem,2017,50(2):71-84.
|
| [4] |
Cymer F,Beck H,Rohde A,et al.Therapeutic monoclonal antibody N-glycosylation-Structure,function and therapeutic potential[J].Biologicals,2018,52:1-11.
|
| [5] |
Li XR,Liu R,Liu FK,et al.Culture process for fully human anti-VEGF165 monoclonal antibody[J].J China Pharm Univ(中国药科大学学报),2015,46(6):734-739.
|
| [6] |
Fan G, Wang Z, Hao M, et al. Bispecific antibodies and their applications[J].J Hematol Oncol,2015,8:130.
|
| [7] |
Brinkmann U,Kontermann RE.The making of bispecific antibodies[J].MAbs,2017,9(2):182-212.
|
| [8] |
Kontermann RE,Brinkmann U.Bispecific antibodies[J].Drug Discov Today,2015,20(7):838-847.
|
| [9] |
Trivedi A,Stienen S,Zhu M,et al.Clinical pharmacology and translational aspects of bispecific antibodies[J].Clin Transl Sci,2017,10(3):147-162.
|
| [10] |
Riesenberg R,Buchner A,Pohla H,et al.Lysis of prostate carcinoma cells by trifunctional bispecific antibodies(alpha EpCAM × alpha CD3)[J].J Histochem Cytochem,2001,49(7):911-917.
|
| [11] |
Sedykh SE,Prinz VV,Buneva VN,et al.Bispecific antibodies:design,therapy,perspectives[J].Drug Des Dev Ther,2018,12:195-208.
|
| [12] |
Kubo M,Umebayashi M,Kurata K,et al.Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines[J].Anticancer Res,2018,38(7):4273-4279.
|
| [13] |
Knödler M,Körfer J,Kunzmann V,et al.Randomised phase II trial to investigate catumaxomab(anti-EpCAM × anti-CD3)for treatment of peritoneal carcinomatosis in patients with gastric cancer[J].Br J Cancer,2018,119(3):296-302.
|
| [14] |
Ruf P,Lindhofer H.Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody[J].Blood,2001,98(8):2526-2534.
|
| [15] |
Heiss MM,Ströhlein MA,Jäger M,et al.Immunotherapy of malignant ascites with trifunctional antibodies[J].Int J Cancer,2005,117(3):435-443.
|
| [16] |
Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody:a phase I/II study[J].Clin Cancer Res,2007,13(13):3899-3905.
|
| [17] |
Heiss MM,Murawa P,Koralewski P,et al.The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer:results of a prospective randomized phase II/III trial[J].Int J Cancer,2010,127(9):2209-2221.
|
| [18] |
Goéré D,Flament C,Rusakiewicz S,et al.Potent immunomodulatory effects of the trifunctional antibody catumaxomab[J].Cancer Res,2013,73(15):4663-4673.
|
| [19] |
Mau-Sørensen M,Dittrich C,Dienstmann R,et al.A phase I trial of intravenous catumaxomab:a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3[J].Cancer Chemother Pharmacol,2015,75(5):1065-1073.
|
| [20] |
Kantarjian H,Stein A,Gökbuget N,et al.Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J].N Engl J Med,2017,376(9):836-847.
|
| [21] |
Ribera JM.Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia[J].Expert Rev Hematol,2017,10(12):1057-1067.
|
| [22] |
Dreier T,Lorenczewski G,Brandl C,et al.Extremely potent,rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody[J].Int J Cancer,2002,100(6):690-697.
|
| [23] |
Topp MS,Stelljes M,Zugmaier G,et al.Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia[J].Leukemia,2018,32(2):562-565.
|
| [24] |
Durer S,Durer C,Shafqat M,et al.Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia:a case report with literature review[J].Immunotherapy,2019,11(5):373-378.
|
| [25] |
Bargou R,Leo E,Zugmaier G,et al.Tumor regression in cancer patients by very low doses of a T cell-engaging antibody[J].Science,2008,321(5891):974-977.
|
| [26] |
Topp MS,Kufer P,Gökbuget N,et al.Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival[J].J Clin Oncol,2011,29(18):2493-2498.
|
| [27] |
Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia[J].J Clin Oncol,2014,32(36):4134-4140.
|
| [28] |
Martinelli G,Boissel N,Chevallier P,et al.Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive b-precursor acute lymphoblastic leukemia following treatment with blinatumomab:results from a phase II,single-arm,multicenter study[J].J Clin Oncol,2017,35(16):1795-1802.
|
| [29] |
Topp MS,Gökbuget N,Stein AS,et al.Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia:a multicentre,single-arm,phase 2 study[J].Lancet Oncol,2015,16(1):57-66.
|
| [30] |
Carter PJ,Lazar GA.Next generation antibody drugs:pursuit of the ‘high-hanging fruit’[J].Nat Rev Discov,2018,17(3):197-223.
|
| [31] |
von Stackelberg A,Locatelli F,Zugmaier G,et al.Phase I/Phase II Study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia[J].J Clin Oncol,2016,34(36):4381-4389.
|
| [32] |
Jen EY,Xu Q,Schetter A,et al.FDA approval:blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease[J].Clin Cancer Res,2019,25(2):473-477.
|
| [33] |
Zhu M,Wu B,Brandl C,et al.Blinatumomab,a bispecific T-cell engager(BiTE®)for CD-19 targeted cancer immunotherapy:clinical pharmacology and its implications[J].Clin Pharmacokinet,2016,55(10):1271-1288.
|
| [34] |
Tammen A,Derer S,Schwanbeck R,et al.Monoclonal antibodies against epidermal growth factor receptor acquire an ability to kill tumor cells through complement activation by mutations that selectively facilitate the hexamerization of igg on opsonized cells[J].J Immunol, 2017,198(4):1585-1594.
|
| [35] |
Mazor Y, Hansen A, Yang C, et al. Insights into the molecular basis of a bispecific antibody′s target selectivity[J].MAbs,2015,7(3):461-469.
|
| [36] |
Mazor Y,Oganesyan V,Yang C,et al.Improving target cell specificity using a novel monovalent bispecific IgG design[J].MAbs,2015,7(2):377-389.
|
| [37] |
Kosaka T,Tanizaki J,Paranal RM,et al.Response heterogeneity of EGFR and HER2 Exon 20 insertions to covalent EGFR and HER2 inhibitors[J].Cancer Res,2017,77(10):2712-2721.
|
| [38] |
Li Y,Hickson JA,Ambrosi DJ,et al.ABT-165,a dual variable domain immunoglobulin(DVD-Ig)targeting DLL4 and VEGF,demonstrates superior efficacy and favorable safety profiles in preclinical models[J].Mol Cancer Ther,2018,17(5):1039-1050.
|
| [39] |
Lee D,Kim D,Choi YB,et al.Simultaneous blockade of VEGF and Dll4 by HD105,a bispecific antibody,inhibits tumor progression and angiogenesis[J].MAbs,2016,8(5):892-904.
|
| [40] |
Klein C,Schaefer W,Regula JT.The use of CrossMAb technology for the generation of bi- and multispecific antibodies[J].MAbs,2016,8(6):1010-1020.
|
| [41] |
Bacac M,Fauti T,Sam J,et al.A Novel Carcinoembryonic antigen T-cell bispecific antibody(CEA TCB)for the treatment of solid tumors[J].Clin Cancer Res,2016,22(13):3286-3297.
|
| [42] |
Lehmann S,Perera R,Grimm HP,et al.In vivo fluorescence imaging of the activity of CEA TCB,a novel T-Cell bispecific antibody,reveals highly specific tumor targeting and fast induction of T-cell-mediated tumor killing[J].Clin Cancer Res,2016,22(17):4417-4427.
|
| [43] |
Wu J,Fu J,Zhang M,et al.AFM13:a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy[J].J Hematol Oncol,2015,8:96.
|
| [44] |
Reusch U,Burkhardt C,Fucek I,et al.A novel tetravalent bispecific TandAb(CD30/CD16A)efficiently recruits NK cells for the lysis of CD30+ tumor cells[J].MAbs,2014,6(3):728-739.
|
| [45] |
Rothe A,Sasse S,Topp MS,et al.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma[J].Blood,2015,125(26):4024-4031.
|
百度学术
下载:
